XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues $ 158,644 $ 131,840
Cost of products sold 119,444 102,440
Gross profit 39,200 29,400
Operating expenses:    
Research and development 7,531 7,081
Selling, general and administrative 22,194 22,190
Total operating expenses 29,725 29,271
Operating income 9,475 129
Other expense (income):    
Interest and financing expense 2,016 951
Miscellaneous income (1,658) (376)
Total other expense, net 358 575
Loss before income taxes 9,117 (446)
Income tax (benefit) provision 1,951 (326)
Net loss 7,166 (120)
Net (loss) income attributable to non-controlling interest (31) (1)
Loss attributable to Ultralife Corporation 7,197 (119)
Other comprehensive (loss) income:    
Foreign currency translation adjustments 90 (2,097)
Comprehensive loss attributable to Ultralife Corporation $ 7,287 $ (2,216)
Net loss per share attributable to Ultralife Corporation common shareholders – Basic (in dollars per share) $ 0.03 $ 0.05
Net loss per share attributable to Ultralife Corporation common shareholders – Diluted (in dollars per share) $ 0.03 $ 0.05
Weighted average shares outstanding – Basic (in shares) 16,214 16,125
Weighted average shares outstanding – Diluted (in shares) 16,226 16,125